RBMA is expecting over 700 radiology business professionals in attendance at its ninth annual PaRADigm conference, along with 65 exhibitors. 

Safety incidents extend the halt at Richmond VA Medical Center into its 19th month, as the United Network for Organ Sharing launches its own investigation following an internal probe by Veterans Affairs.

The U.S. Department of Justice is appealing a lower court’s ruling that would see 16,000 federal employees return to work, including many from Veterans Affairs. 

The subcutaneous drug, sold under the brand name Amvuttra, joins an ATTR-CM market that already includes Pfizer’s tafamidis (Vyndaqel, Vyndamax) and BridgeBio’s acoramidis (Attruby).

By the time the patient was diagnosed with advanced stage lung cancer, his tumor was double the size it was when it first appeared on imaging in 2017. 

Abbott has received an investigational device exemption from the FDA for a new clinical trial evaluating the safety and effectiveness of using its coronary IVL technology. The trial is expected to enroll up to 335 U.S. patients.

A new analysis calls into question the use of imaging alone to determine the efficacy of ablative radiation therapy. 

Steven Bolling, MD, noted that tricuspid treatments have been linked to consistent benefits in terms of quality of life. However, he said, finding clear improvements in clinical outcomes has been more challenging.

The drug in question, ataciguat, could help heart patients avoid aortic valve replacement—or at least put it off until later in life.

As coronary CT angiography (CCTA) continues its rapid expansion, scanner vendors are now offering more economical solutions to ensure access to imaging technology beyond premium systems most often only found at flagship hospitals and academic centers. To conquer CCTA’s technical challenges, new technologies and AI are being incorporated into a new scanner to simplify acquisition and consistently improve image quality.